

# Risk for hospitalization for heart failure down with SGLT-2i treatment for T2D

May 24 2022

---



For patients with type 2 diabetes (T2D) receiving first-line sodium-

glucose cotransporter-2 inhibitors (SGLT-2i), the risk for stroke, myocardial infarction (MI), and all-cause mortality is similar to those receiving metformin, and the risk for hospitalization for heart failure (HHF) is lower, according to a study published online May 24 in the *Annals of Internal Medicine*.

HoJin Shin, Ph.D., from Brigham and Women's Hospital and Harvard Medical School in Boston, and colleagues conducted a population-based cohort study involving patients with T2D aged 18 years and older initiating treatment with SGLT-2i or metformin during April 2013 to March 2020 using claims data from two large U.S. commercial and Medicare databases (8,613 and 17,226 [patients](#), respectively).

The researchers found that during a mean follow-up of 12 months, SGLT-2i initiators had a similar risk for the composite of hospitalization for MI, hospitalization for ischemic or [hemorrhagic stroke](#), or all-cause mortality (MI/stroke/mortality) and a lower risk for the composite of HHF or all cause-mortality (HHF/mortality). Compared with metformin, initiators receiving SGLT-2i had a significantly lower risk for HHF, a numerically lower risk for MI, and a similar risk for stroke, mortality, and MI/stroke/HHF/mortality. The risk for genital infections was increased for initiators receiving SGLT-2i; otherwise, safety was similar.

"Although our findings may support the use of SGLT-2i as first-line T2D treatment of cardiovascular outcomes, further research, that is, a randomized clinical trial, is warranted to establish more robust evidence," the authors write.

**More information:** [Abstract/Full Text \(subscription or payment may be required\)](#)



Citation: Risk for hospitalization for heart failure down with SGLT-2i treatment for T2D (2022, May 24) retrieved 22 November 2023 from <https://medicalxpress.com/news/2022-05-hospitalization-heart-failure-sgl-2i-treatment.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.